Synaffix
Latest round
- Series A
Last raised
- Feb 2014
Total raised
- Undisclosed
Investors
- 4
About Synaffix
Founded in 2010 in Oss, Netherlands, Synaffix BV is focused on advancing biopharmaceutical technologies, specifically in the field of ADCs. Under the leadership of CEO Peter Van de Sande, the company has completed 2 deals, with the most recent on June 1, 2023, when it underwent a TRADE SALE to Lonza Group Ltd.Synaffix specializes in providing advanced biopharmaceutical technologies with a focus on antibody-drug conjugates (ADCs) and bispecific antibodies. Its proprietary platform technology, centered around the antibody glycan, allows partner companies to develop customized, state-of-the-art ADCs that target cancer therapeutics more effectively. The company’s technology is designed for rapid deployment, enabling biopharmaceutical organizations to integrate these capabilities into their own pipelines. Synaffix's client base includes prominent pharmaceutical companies engaged in oncology, particularly in North America, Europe, and Asia.Synaffix operates under a focused technology out-licensing business model, generating revenue primarily through licensing agreements and partnerships with pharmaceutical companies. The company enters into contracts with clients for the use of its ADC technology, facilitating a transition from preclinical development to clinical trials and potential commercialization. Revenue transactions are structured as B2B partnerships, where pharmaceutical firms license Synaffix’s technology to augment their oncology pipelines. These agreements often involve milestone payments and royalties contingent upon the successful advancement of therapeutic candidates through various clinical phases. Synaffix’s notable collaborations include licensing arrangements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma, contributing to a robust framework for revenue generation within the biopharmaceutical sector.With the acquisition by Lonza Group Ltd. occurring on June 1, 2023, the firm aims to leverage this partnership to enhance its bioconjugates offerings. Looking ahead, Synaffix is expected to focus on developing new ADC products and expanding into additional markets, particularly targeting North America and Asia.
Who invested in Synaffix
4 investors across 1 round
See all investors in Synaffix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 18, 2014
Amount
Undisclosed
Investors
Questions about Synaffix
Who invested in Synaffix?
Synaffix has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Synaffix raised?
Synaffix has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Synaffix last raise money?
Synaffix's most recent round on record is a Series A, in Feb 2014.
What does Synaffix do?
Founded in 2010 in Oss, Netherlands, Synaffix BV is focused on advancing biopharmaceutical technologies, specifically in the field of ADCs.
Where is Synaffix headquartered?
Synaffix is headquartered in Oss, Netherlands.
Which VCs invest in companies like Synaffix?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Synaffix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Synaffix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.